SCHEMBL5480164

SCHEMBL5480164

Cn1c(Cl)nc2c1NC(=O)C2(c1ccc(NS(C)(=O)=O)cc1)c1ccc(NS(C)(=O)=O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.38
BRPF1 P55201 1/20 0.37
ALDH1A1 P00352 2/20 0.36
PGR P06401 2/20 0.36
KDM5B Q9UGL1 1/20 0.34
P2RX3 P56373 1/20 0.34
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KAT2B Q92831 1/20 0.33
HAVCR2 Q8TDQ0 1/20 0.33
DCLK1 O15075 1/20 0.33
MAPK1 P28482 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
KEAP1 Q14145 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482013 0.80 CYP19A1 (0.34) ALDH1A1KDM4E
SCHEMBL5478021 0.80 CHRM2 (0.39) ALDH1A1KDM4EHTTKCNH2PTGS2
SCHEMBL5478439 0.78 ALDH1A1 (0.37) ALDH1A1KDM4ELMNAHPGDHTT
SCHEMBL5483547 0.74 SMN1; SMN2 (0.37) KIF11BRPF1ALDH1A1PGRKDM4E
SCHEMBL5478102 0.69 KEAP1 (0.38) KIF11BRPF1ALDH1A1PGRKDM4E
SCHEMBL5482571 0.67 KIF11 (0.40) KIF11ALDH1A1PGRKDM4ELMNA
SCHEMBL5474271 0.67 KIF11 (0.40) KIF11ALDH1A1PGRKDM4ELMNA
SCHEMBL5485549 0.67 KIF11 (0.40) KIF11ALDH1A1PGRKDM4ELMNA
SCHEMBL5484218 0.66 KIF11 (0.42) KIF11ALDH1A1PGRKDM4ELMNA
SCHEMBL5482451 0.64 SMN1; SMN2 (0.38) KIF11ALDH1A1PGRKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 KIF11 4188/4885BRPF1 2902/4885ALDH1A1 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.